Literature DB >> 29569506

Impact of allergen immunotherapy in allergic asthma.

Wenming Zhang1, Chunrong Lin1, Vanitha Sampath1, Kari Nadeau1.   

Abstract

Although traditional pharmacological approaches improve outcomes in disease management for allergic asthma, these fail to modify the underlying immune responses. Allergen immunotherapy remains the only etiological therapy for the treatment of respiratory allergies for which clinical efficacy has been demonstrated through several well-controlled studies. In this review, we examine evidence from the past 5 years regarding the impact of allergen immunotherapy on allergic asthma to inform practitioners and stimulate further discussion and research.

Entities:  

Keywords:  allergen immunotherapy (AIT); allergic asthma; mechanisms; omalizumab; subcutaneous immunotherapy (SCIT); sublingual immunotherapy (SLIT)

Mesh:

Substances:

Year:  2018        PMID: 29569506      PMCID: PMC5994829          DOI: 10.2217/imt-2017-0138

Source DB:  PubMed          Journal:  Immunotherapy        ISSN: 1750-743X            Impact factor:   4.196


  104 in total

1.  House dust mite sublingual immunotherapy is safe in patients with mild-to-moderate, persistent asthma: a clinical trial.

Authors:  P Devillier; R Fadel; O de Beaumont
Journal:  Allergy       Date:  2015-11-06       Impact factor: 13.146

Review 2.  Bronchial hyperresponsiveness.

Authors:  J Borak; R Y Lefkowitz
Journal:  Occup Med (Lond)       Date:  2015-11-20       Impact factor: 1.611

3.  Safety Review of 5-Grass Pollen Tablet from Pooled Data of Clinical Trials.

Authors:  Thomas B Casale; Linda S Cox; Ulrich Wahn; David B K Golden; Brigitte Bons; Alain Didier
Journal:  J Allergy Clin Immunol Pract       Date:  2017-07-19

4.  Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study).

Authors:  Christian Möller; Sten Dreborg; Hosne A Ferdousi; Susanne Halken; Arne Høst; Lars Jacobsen; Antti Koivikko; Dieter Y Koller; Bodo Niggemann; Lene A Norberg; Radvan Urbanek; Erkka Valovirta; Ulrich Wahn
Journal:  J Allergy Clin Immunol       Date:  2002-02       Impact factor: 10.793

Review 5.  Emerging interleukin receptor antagonists for the treatment of asthma.

Authors:  Khalid Al Efraij; J Mark FitzGerald
Journal:  Expert Opin Emerg Drugs       Date:  2017-08-23       Impact factor: 4.191

6.  Suppression of the late asthmatic reaction by hyposensitization in asthmatic children allergic to house dust mite (Dermatophagoides pteronyssinus).

Authors:  H P Van Bever; W J Stevens
Journal:  Clin Exp Allergy       Date:  1989-07       Impact factor: 5.018

Review 7.  Subcutaneous and Sublingual Immunotherapy in Allergic Asthma in Children.

Authors:  Sophia Tsabouri; Antigoni Mavroudi; Gavriela Feketea; George V Guibas
Journal:  Front Pediatr       Date:  2017-04-21       Impact factor: 3.418

8.  Comparison of the immunogenicity of BM32, a recombinant hypoallergenic B cell epitope-based grass pollen allergy vaccine with allergen extract-based vaccines.

Authors:  Milena Weber; Katarzyna Niespodziana; Birgit Linhart; Angela Neubauer; Hans Huber; Rainer Henning; Rudolf Valenta; Margarete Focke-Tejkl
Journal:  J Allergy Clin Immunol       Date:  2017-05-31       Impact factor: 10.793

Review 9.  EAACI position statement on asthma exacerbations and severe asthma.

Authors:  A Custovic; S L Johnston; I Pavord; M Gaga; L Fabbri; E H Bel; P Le Souëf; J Lötvall; P Demoly; C A Akdis; D Ryan; M J Mäkelä; F Martinez; J W Holloway; S Saglani; P O'Byrne; A Papi; S Sergejeva; A Magnan; S Del Giacco; O Kalayci; E Hamelmann; N G Papadopoulos
Journal:  Allergy       Date:  2013-11-06       Impact factor: 13.146

10.  GATA3-driven Th2 responses inhibit TGF-beta1-induced FOXP3 expression and the formation of regulatory T cells.

Authors:  Pierre-Yves Mantel; Harmjan Kuipers; Onur Boyman; Claudio Rhyner; Nadia Ouaked; Beate Rückert; Christian Karagiannidis; Bart N Lambrecht; Rudolf W Hendriks; Reto Crameri; Cezmi A Akdis; Kurt Blaser; Carsten B Schmidt-Weber
Journal:  PLoS Biol       Date:  2007-12       Impact factor: 8.029

View more
  6 in total

1.  Immune Modulation of Allergic Asthma by Early Pharmacological Inhibition of RIP2.

Authors:  Madelyn H Miller; Michael G Shehat; Justine T Tigno-Aranjuez
Journal:  Immunohorizons       Date:  2020-12-18

2.  Artemisia sieversiana pollen allergy and immunotherapy in mice.

Authors:  Qian Zhang; Guangpeng Xi; Jia Yin
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

3.  Use of Systemic Corticosteroids for Reasons Other than Asthma in Subjects with Asthma.

Authors:  Keisuke Watanabe; Nobuyuki Horita; Yu Hara; Nobuaki Kobayashi; Takeshi Kaneko
Journal:  Respiration       Date:  2021-09-01       Impact factor: 3.966

4.  Development of a Novel Targeted Metabolomic LC-QqQ-MS Method in Allergic Inflammation.

Authors:  David Obeso; Nuria Contreras; Mariana Dolores-Hernández; Teresa Carrillo; Coral Barbas; María M Escribese; Alma Villaseñor; Domingo Barber
Journal:  Metabolites       Date:  2022-06-25

Review 5.  Asthma and COVID-19: What do we know now.

Authors:  Alexzandra Hughes-Visentin; Anthea B Mahesan Paul
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2020-10-23

6.  Effectiveness of Sublingual Immunotherapy in the Treatment of HDM-Induced Nasobronchial Allergies: A 3-Year Randomized Case-Control Study From Kashmir.

Authors:  Shahid M Baba; Roohi Rasool; Ayaz Gull; Taha A Qureshi; Afaq H Beigh; Qurteeba Qadri; Zafar A Shah
Journal:  Front Immunol       Date:  2021-10-13       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.